Dr. Reddy's Laboratories Limited (NSE:DRREDDY)

India flag India · Delayed Price · Currency is INR
1,287.40
+9.50 (0.74%)
Jul 28, 2025, 3:30 PM IST
0.74%
Market Cap1.07T
Revenue (ttm)334.26B
Net Income (ttm)56.80B
Shares Outn/a
EPS (ttm)68.11
PE Ratio18.85
Forward PE20.65
Dividend8.00 (0.62%)
Ex-Dividend DateJul 10, 2025
Volume1,553,743
Average Volume1,414,608
Open1,280.00
Previous Close1,277.90
Day's Range1,271.60 - 1,290.00
52-Week Range1,020.00 - 1,421.50
Beta0.38
RSI54.25
Earnings DateJul 23, 2025

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages i... [Read more]

Sector Healthcare
Founded 1984
Employees 27,811
Stock Exchange National Stock Exchange of India
Ticker Symbol DRREDDY
Full Company Profile

Financial Performance

In 2024, Dr. Reddy's Laboratories's revenue was 325.54 billion, an increase of 16.61% compared to the previous year's 279.16 billion. Earnings were 56.54 billion, an increase of 1.54%.

Financial Statements

News

This Indian pharma company sees a big opportunity in generic versions of weight-loss drugs

Dr. Reddy's Laboratories is betting big on a new wave of growth fueled by a global demand for weight-loss drugs.

4 days ago - CNBC

Big Indian pharma is coming for Ozempic and Wegovy

Dr. Reddy's CEO Erez Israeli talks about the Indian pharma's plans to introduce a low-cost generic version of semaglutide - the active ingredient used in blockbuster weight-loss drugs Wegovy and Ozemp...

4 days ago - CNBC

Dr. Reddy’s shares jump over 3% following Q1 results – Should you buy, hold or sell? Know More

Shares of Dr. Reddy’s Laboratories surged 3.06% to Rs 1,285.60 on Wednesday after the company reported its Q1 FY26 financial results. The stock touched an intraday high of Rs 1,287.90 and now commands...

4 days ago - Business Upturn

Dr Reddy’s stock: CLSA, Jefferies recommend sell, Morgan Stanley says hold — here’s why

Top brokerages have delivered a mixed outlook on Dr. Reddy’s Laboratories following its Q1FY26 results. While Jefferies and CLSA retained their Underperform ratings citing concerns over U.S. business ...

4 days ago - Business Upturn

Dr Reddy’s share: Morgan Stanley maintains equal-weight, sets Rs 1,298 target after Q1 margin pressure

Morgan Stanley has maintained its Equal-Weight rating on Dr. Reddy’s Laboratories, assigning a target price of ₹1,298 per share. The target indicates a modest upside from the current market price of ₹...

4 days ago - Business Upturn

Dr Reddy’s share: Jefferies sees 12% downside after Q1 miss, cuts target to Rs 1,100

Jefferies has maintained its Underperform rating on Dr. Reddy’s Laboratories, lowering expectations with a target price of ₹1,100 per share. This implies a 12% downside from the current market price o...

4 days ago - Business Upturn

Dr Reddy’s share: CLSA sees 10% downside, flags tapering US momentum and gRevlimid slowdown

CLSA has maintained its Underperform rating on Dr. Reddy’s Laboratories, assigning a target price of ₹1,120 per share, implying a 10% downside from the current market price of ₹1,248.00. The brokerage...

4 days ago - Business Upturn

Dr Reddy’s PAT rises 2% despite record quarterly revenues in Q1FY26

Hyderabad: Despite clocking its highest-ever quarterly revenues during the first quarter ended June 30, pharma major Dr Reddy's Laboratories (DRL) on .

5 days ago - The Times of India

Dr. Reddy's Q1FY26 Financial Results

HYDERABAD, India--(BUSINESS WIRE)---- $RDY #ConsolidatedFinancialResults--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2025.

5 days ago - Business Wire

India's Dr Reddy's to launch generic obesity drugs in 87 countries next year, CEO says

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 countries next year, the Indian drugmaker's CEO, Erez Israeli, said on Wed...

5 days ago - Reuters

Dr Reddy’s Laboratories Q1 Results: Revenue jumps 11.4% YoY to Rs 8,545 crore, net profit marginally up

Dr. Reddy’s Laboratories kicked off the fiscal year on a solid note, posting its Q1 FY26 results with a healthy revenue increase but a slight dip in margins. The Hyderabad-based pharma giant reported ...

5 days ago - Business Upturn

Q1FY26 results today: Infosys, Tata Consumer, Dr Reddy’s, SRF, Persistent among 40 companies to announce earnings on July 23

Investors will closely watch quarterly earnings from several key companies scheduled to report their Q1FY26 results today, July 23, 2025. Among the most anticipated are Infosys, Tata Consumer Products...

5 days ago - Business Upturn

Q1 Results Today, 23rd July: Infosys, Dr Reddy’s, Tata Consumer, Coforge among top companies

India Inc.’s earnings season picks up pace today as several leading companies across sectors are set to announce their financial results for the quarter ended June 30, 2025 (Q1 FY26). After bellwether...

5 days ago - Business Upturn

Dr. Reddy's Q1 Earnings Preview

6 days ago - Seeking Alpha

Top stocks to watch today, July 22: Titan, UltraTech, Dr Reddy’s in focus; Havells, Bajaj Finance under pressure

A host of stocks are likely to remain in focus on Monday, July 22, driven by fresh corporate developments, Q1 earnings announcements, and new brokerage commentary. Here are the key names to track: Pos...

6 days ago - Business Upturn

Why Is Alvotech Stock Trading Higher On Wednesday?

Alvotech (NASDAQ: ALVO) shares saw a positive lift Wednesday morning following the announcement that the biosimilar developer has significantly bolstered its production capabilities by acquiring Swis...

19 days ago - Benzinga

Nifty top losers today, July 8: Titan Company, Dr. Reddy’s Laboratories, Cipla, Bajaj Auto, Trent and more

Indian stock markets closed Monday, July 8, on a positive note, with both benchmark indices finishing in the green. The Sensex gained 270.01 points to settle at 83,712.51, while the Nifty 50 edged up ...

20 days ago - Business Upturn

Nifty top gainers today, July 4: Bajaj Finance, Dr. Reddy’s, Infosys, Hindustan Unilever, ICICI Bank and more

Indian equity benchmarks ended the July 4 trading session on a positive note, despite intraday volatility. The BSE Sensex gained 193.42 points, or 0.23%, to close at 83,432.89. Meanwhile, the NSE Nift...

24 days ago - Business Upturn

Nifty 50 top gainers today, July 3: Dr. Reddy’s, Apollo Hospitals, Hero MotoCorp, ONGC and more

Indian equity markets closed in the red on Wednesday, July 3, after a choppy trading session. The benchmark indices slipped slightly, with the Sensex falling 170 points to settle at 83,239.47, while t...

25 days ago - Business Upturn

Nifty 50 top losers this week (June 28): ONGC, Dr. Reddy’s, Tech Mahindra, Maruti Suzuki India and more

Indian stock markets wrapped up the week on a strong note, with benchmark indices extending their gains for the second consecutive week. Both the Sensex and Nifty 50 advanced over 2%, supported by bro...

4 weeks ago - Business Upturn

Nifty 50 top losers today, June 27: Tata Consumer Products, Dr. Reddy’s, Wipro, SBI Life and more

Indian stock markets ended on a high note on June 27, with the Sensex rising 303 points to 84,058.90 and the Nifty gaining 88.80 points to close at 25,637.80. However, not all stocks shared in the ral...

4 weeks ago - Business Upturn